These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20551956)

  • 1. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.
    Kelly P; Appleyard V; Murray K; Paulin F; Lamont D; Baker L; Suttie S; Exon D; Thompson A
    Br J Cancer; 2010 Jul; 103(2):232-8. PubMed ID: 20551956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer.
    Kelly P; Paulin F; Lamont D; Baker L; Clearly S; Exon D; Thompson A
    Br J Cancer; 2012 Feb; 106(5):955-61. PubMed ID: 22294182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
    Aichler M; Elsner M; Ludyga N; Feuchtinger A; Zangen V; Maier SK; Balluff B; Schöne C; Hierber L; Braselmann H; Meding S; Rauser S; Zischka H; Aubele M; Schmitt M; Feith M; Hauck SM; Ueffing M; Langer R; Kuster B; Zitzelsberger H; Höfler H; Walch AK
    J Pathol; 2013 Aug; 230(4):410-9. PubMed ID: 23592244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
    Starling N; Okines A; Cunningham D; Allum W; Wotherspoon A; Benson M; Thompson J; Thomas J; Brown G; Riddell A; Stavridi F; Ashley S; Oates J; Chau I
    Br J Cancer; 2009 Jun; 100(11):1725-30. PubMed ID: 19436301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
    Mackay HJ; McInnes A; Paul J; Raby N; Lofts FJ; McDonald AC; Soukop M; Fullarton GM; Harris AL; Garcia-Vargas J; Evans TR
    Ann Oncol; 2001 Oct; 12(10):1407-10. PubMed ID: 11762812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
    Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
    Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
    Highley MS; Parnis FX; Trotter GA; Houston SJ; Penson RT; Harper PG; Mason RC
    Br J Surg; 1994 Dec; 81(12):1763-5. PubMed ID: 7530150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
    Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
    Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
    Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
    Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
    Strickland AH; Karapetis CS; Yip D; Harper PG
    Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143
    [No Abstract]   [Full Text] [Related]  

  • 13. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
    Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
    J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
    Melcher AA; Mort D; Maughan TS
    Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
    Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
    Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS.
    Guo N; Minas G; Synowsky SA; Dunne MR; Ahmed H; McShane R; Bhardwaj A; Donlon NE; Lorton C; O'Sullivan J; Reynolds JV; Caie PD; Shirran SL; Lynch AG; Stewart AJ; Arya S
    J Proteomics; 2022 Aug; 266():104684. PubMed ID: 35842220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Probable choroid metastasis of an esophageal adenocarcinoma that regressed with chemotherapy].
    Caroli-Bosc FX; Caujolle C; Gastaud P; Montoya ML; Demarquay JF; Delmont JP
    Gastroenterol Clin Biol; 1998 Mar; 22(3):359-60. PubMed ID: 9762224
    [No Abstract]   [Full Text] [Related]  

  • 19. Proteomic Protocol in Esophageal Adenocarcinoma.
    Kelly P
    Methods Mol Biol; 2018; 1756():281-293. PubMed ID: 29600378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.